Inventor

Robert L. Hudkins

Inventor

Chester Springs, PA, US

Overview

1987–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 68 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary

C07DHeterocyclic compounds37%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations36%

A61KPreparations for medical, dental or toiletry purposes17%

C07HSugars3%

Y02ATechnologies for adaptation to climate change2%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%

C09BOrganic dyes or closely-related compounds for producing dyes, e.g. pigments2%

C07CAcyclic or carbocyclic compounds1%

PatentTitleYear

11,046,707Spiropiperidine derivatives2021 10,919,875Substituted 4-benzyl and 4-benzoyl piperidine derivatives2021 10,851,0571,4-substituted piperidine derivatives2020 10,414,763Azaquinazoline inhibitors of atypical protein kinase C2019 10,221,1351,4-substituted piperidine derivatives2019 10,028,956Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents2018 10,017,496Uracil derivatives as AXL and c-MET kinase inhibitors2018 9,914,730'Azaquinazoline inhibitors of Atypical protein Kinase C'2018 9,914,731'Pyrazolo[1,5-a]pyridine derivatives and methods of their use'2018 9,902,696'1,4-substituted piperidine derivatives'2018 9,896,446'Azaquinazoline inhibitors of atypical protein kinase C'2018 9,745,283'Uracil derivatives as AXL and c-MET kinase inhibitors'2017 9,522,902'Uracil derivatives as AXL and c-MET kinase inhibitors'2016 9,120,778'Uracil derivatives as AXL and c-MET kinase inhibitors'2015 9,029,538'Uracil derivatives as AXL and c-MET kinase inhibitors'2015 8,912,183'Substituted pyridazine derivatives'2014 8,716,493'Multicyclic compounds and the use thereof'2014 8,673,916'Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives'2014 8,648,067'Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands'2014 8,586,588'Aryl pyridazinone derivatives and their use as H3 receptor ligands'2013 8,524,713'Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands'2013 8,513,232'Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands'2013 8,471,005'Pyrrolotriazines as ALK and JAK2 inhibitors'2013 8,383,813'Fused pyrrolocarbazoles'2013 8,354,414'Substituted bicyclic pyrimidines'2013 8,247,414'Pyridizinone derivatives and the use thereof as H3 inhibitors'2012 8,207,168'Pyridazinone derivatives'2012 8,084,472'Fused pyrrolocarbazoles'2011 8,076,331'Substituted pyridazine derivatives'2011 8,044,064'Fused pyrrolocarbazoles'2011 7,851,468'Substituted pyrazolo[3,4-d]pyrimidines'2010 7,789,610'Methods for preventing/treating damage to sensory hair cells and cochlear neurons'2010 7,732,447'Fused [d]pyridazin-7-ones'2010 7,671,064'Fused pyrrolocarbazoles'2010 7,514,440'Fused pyrrolocarbazoles'2009 7,291,732'Isomeric fused pyrrolocarbazoles and isoindolones'2007 7,288,650'Cyclic substituted fused pyrrolocarbazoles and isoindolones'2007 7,241,779'Fused pyrrolocarbazoles'2007 7,230,026'Selected fused pyrrolocarbazoles'2007 7,169,802'Fused pyrrolocarbazoles'2007 7,122,679'Multicyclic compounds and the use thereof'2006 7,115,613'Selected fused pyrrolocarbazoles'2006 7,074,793'Cyclic substituted fused pyrrolocarbazoles and isoindolones'2006 7,018,999'Methods for the treatment and prevention of pain'2006 6,875,865'Selected derivatives of K-252a'2005 6,872,746'Isomeric fused pyrrolocarbazoles and isoindolones'2005 6,841,567'Cyclic substituted fused pyrrolocarbazoles and isoindolones'2005 RE038332'Selected soluble esters of hydroxyl-containing indolocarbazoles'2003 6,635,669'Isomeric fused pyrrolocarbazoles and isoindolones'2003 6,630,500'Selected fused pyrrolocarbazoles'2003 6,451,786'3-epimeric k-252a derivatives'2002 6,448,283'Methods for preventing/treating damage to sensory hair cells and cochlear neurons'2002 6,399,780'Isomeric fused pyrrolocarbazoles and isoindolones'2002 6,359,130'Bridged indenopyrrolocarbazoles'2002 6,306,849'Selected derivatives of K-252a'2001 6,127,401'Bridged indenopyrrolocarbazoles'2000 6,093,713'3\'-epimeric K-252A derivatives'2000 5,808,060'Fused isoindolones'1998 5,801,190'Fused pyrrolo›2,3-C! carbazole-6-ones'1998 5,705,511'Fused pyrrolocarbazoles'1998 5,686,444'Selected soluble esters of hydroxyl-containing indolocarbazoles'1997 5,650,407'Selected soluble esters of hydroxyl-containing indolocarbazoles'1997 5,616,724'Fused pyrrolo[2,3-c]carbazole-6-ones'1997 5,594,009'Fused pyrrolocarbazoles'1997 5,591,855'Fused pyrrolocarbazoles'1997 5,516,772'K-252 derivatives which enhance neurotrophin-induced activity'1996 5,475,110'Fused Pyrrolocarbazoles'1995 4,657,899'Antagonists of specific excitatory amino acid neurotransmitter receptors'1987

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1987Based in Baltimore, MD, US· patent location history

1995–2018Patents assigned to CEPHALON INC (53)· patent assignee history

1995–2021Based in Chester Springs, PA, US· patent location history

2011–2014Patents assigned to HUDKINS ROBERT L (14)· patent assignee history

2011–2014Patents assigned to ZULLI ALLISON L (9)· patent assignee history

2012–2014Patents assigned to BECKNELL NADINE C (7)· patent assignee history

2015–2018Patents assigned to IGNYTA INC (9)· patent assignee history

2018Based in San Diego, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
CEPHALON INC	53	1995–2018
HUDKINS ROBERT Lself	14	2011–2014
IGNYTA INC	9	2015–2018
ZULLI ALLISON L	9	2011–2014
BECKNELL NADINE C	7	2012–2014

Locations

Location	Patents	Span
Chester Springs, Pennsylvania, US	66	1995–2021
San Diego, California, US	1	2018
Baltimore, Maryland, US	1	1987